Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

SARS-CoV-2 and its vaccine/immune-escaping variants continue to pose a serious threat to public health due to a paucity of effective, rapidly deployable, and widely available treatments. Here, we address these challenges by combining Pegasys (IFNα) and nafamostat to effectively suppress SARS-CoV-2 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ianevski, Aleksandr, Yao, Rouan, Lysvand, Hilde, Grødeland, Gunnveig, Legrand, Nicolas, Oksenych, Valentyn, Zusinaite, Eva, Tenson, Tanel, Bjørås, Magnar, Kainov, Denis E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473362/
https://www.ncbi.nlm.nih.gov/pubmed/34578348
http://dx.doi.org/10.3390/v13091768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473362/
https://www.ncbi.nlm.nih.gov/pubmed/34578348
http://dx.doi.org/10.3390/v13091768

Ejemplares similares